High Quality Dihexa Powder CAS 1401708-83-5 98% PNB-0408 Research Raw Material
TDS 173 Inquiries
1401708-83-5
Pharmaceutical Grade
99%
Xi'an
FULECARE
Double plastic bags plus aluminum foil bag
2027-12-30
Slu-pp-332,BAM 15
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Dihexa is a synthetic peptide-based compound and angiotensin IV analog. As a research and pharmaceutical raw material, Dihexa is characterized by its defined molecular structure and peptide properties. It is primarily used for research, analytical testing, compound evaluation, and pharmaceutical development.
CertificatesBasic Info-
Product Name:
Dihexa
Other Name:L-Isoleucinamide,N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide;Dihexa;N-Hexanoic-Tyr-Ile-(6)aminohexanoic amide
CAS No.:1401708-83-5
Molecular Formula:C27H44N4O5
InChIKeys:InChIKey=XEUVNVNAVKZSPT-JTJYXVOQSA-N
Molecular Weight:504.7
Exact Mass:504.66
Categories:
Characteristics-
Density:
1.111±0.06 g/cm3(Predicted)
Boiling Point:866.2±65.0 °C(Predicted)
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Slu-pp-332,BAM 15
-
Location:
No. 11608, 16th Floor, Unit 1, Building 1, West of Zhangba Liu Road, South Third Ring Road, High tech Zone, Xi'an City, Shaanxi Province
-
Payment Terms:
L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
335 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2025
-
-
Inquiry History173 Inquiries
Country Product Purchase Quantity Date Posted
Canada
Dihexa lyophilized 1401708-83-5
1 Aug 23, 2026
Canada
Dihexa 1401708-83-5
1 G Mar 8, 2026
Bulgaria
Customized peptides high purity Dihexa with fast shipping door to door CAS 1401708-83-5
10 G May 27, 2025
United States
Dihexa
500 G Aug 19, 2026
United States
Dihexa
25 G Jan 26, 2025
Russia
DIHEXA
50.00 G Aug 14, 2024
United States
Dihexa
10 G Sep 9, 2026
India
Dihexa
10 MG Sep 4, 2026
Norway
Dihexa
1 G Aug 26, 2026
United States
Dihexa
1 G Aug 22, 2026
United States
Dihexa
1 G Aug 4, 2026
United States
Dihexa
1 G Jul 30, 2026
United States
Dihexa
1 G Jul 8, 2026
United States
Dihexa
10 MG Jul 6, 2026
Australia
Dihexa
1 G Jun 30, 2026
United States
Dihexa Peptide Nootropic Neurotrophy Dihexa Powder (Pharmaceutical Grade)
1.0 G Jun 5, 2026
United States
Dihexa
1 MT May 9, 2026
United States
dihexa
1 KG May 8, 2026
Canada
Dihexa
3 G May 7, 2026
United States
Dihexa
123456 G May 4, 2026 Post an enquiry for this product
More from this Seller
-
-
-
High Quality Food Grade Magnesium Glycinate Powder CAS 14783-68-7 13% Elemental Magnesium Chelated Mineral Supplement Raw Material
Pharmaceutical Grade / 99%
$13-15/KG FOB
-
-
-
-
High Quality SM04554 Dalosirvat Powder CAS 1360540-81-3 Wnt Activator Anti-Hair Loss Research Raw Material
Pharmaceutical Grade / 99%
$80-100/G FOB
-
-
-
-
High Quality Pure 98% Rgpu-95 Raw Powder CAS 213178-69-9 Factory Supply
Industrial Grade / 99%
-
-
-
-
Bulk NACET N-Acetyl-L-Cysteine Ethyl Ester CAS 59587-09-6 for Antioxidant Formula Research
Pharmaceutical Grade / 99%
$2.5-3/G FOB
-
-
-
-
Enclomiphene Citrate Factory Supply Best Price Pure 99% Enclomiphene Citrate Powder CAS 7599-79-3
Pharmaceutical Grade / 99%
-
